Real-world study examines breast cancer drug's effectiveness outside clinical trials

NCT ID NCT06784921

Recruiting now Knowledge-focused Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will review medical records of 200 patients in China with HER2-negative metastatic breast cancer who received sacituzumab govitecan. Researchers want to see how long the drug keeps cancer from growing and how well patients tolerate it. The goal is to understand real-world outcomes beyond controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sacituzumab govitecan
What this could lead to: If successful, this study could confirm that sacituzumab govitecan is effective and safe for HER2-negative metastatic breast cancer patients in real-world settings.
What could go wrong: This is a retrospective study, so it looks at past data and cannot prove cause and effect. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER, METASTATIC

Contacts and locations

Locations

Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.